4.3 Article

Evaluation of Intensity-Based Ratiometric FRET in Image Cytometry-Approaches and a Software Solution

期刊

CYTOMETRY PART A
卷 75A, 期 9, 页码 761-767

出版社

WILEY
DOI: 10.1002/cyto.a.20747

关键词

fluorescence resonance energy transfer; ratiometric FRET; intensity-based FRET; FRET calibration; confocal laser scanning microscopy; ImageJ; 3D image processing

向作者/读者索取更多资源

The intensity-based ratiometric FRET (fluorescence resonance energy transfer) method is a powerful technique for following molecular interactions in living cells. Since it is not based on irreversibly destroying the donor or the acceptor fluorophores, the time course of changes in FRET efficiency values can be monitored by this method. ImageJ, a sophisticated software tool for many types of image processing allows users to extend it with programs for various purposes. Implementing intensity-based ratiometric FRET with ImageJ vastly enhances the applicability of the FRET method. We developed an efficient ImageJ plugin, RiFRET, which calculates FRET efficiency on a pixel-by-pixel basis from ratiometric FRET images. It allows the user to correct for channel cross-talk (bleed-through) and to calculate FRET from image stacks, i.e., from 3D data sets. Semiautomatic processing for larger datasets is also included in the program. Furthermore, several options for calibrating FRET efficiency calculations were tested and their applicability to various expression systems is discussed. Although the ratiometric FRET method is widely applied, our plugin is the first freely available software for evaluating such FRET data. The program is user friendly and provides reliable, standardized results. (C) 2009 international Society for Advancement of cytometry

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

Anandamide Concentration-Dependently Modulates Toll-Like Receptor 3 Agonism or UVB-Induced Inflammatory Response of Human Corneal Epithelial Cells

Agnes Angyal, Zsofia Penzes, Shahrzad Alimohammadi, Dorottya Horvath, Lili Takacs, Gyorgy Vereb, Barbara Zsebik, Tamas Biro, Kinga Fanni Toth, Erika Lisztes, Balazs Istvan Toth, Attila Olah, Attila Gabor Szollosi

Summary: The study found that human corneal epithelial cells express members of the endocannabinoid system, playing a role in inflammatory responses. Despite previous reports on the anti-inflammatory potential of endocannabinoids, their effects on the immune phenotype of human corneal epithelium may be more complex and context dependent.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Review Oncology

Single-Cell Sequencing: Current Applications in Precision Onco-Genomics and Cancer Therapeutics

Lisa Maria Mustachio, Jason Roszik

Summary: Single-cell sequencing technologies have become increasingly important in cancer research, allowing scientists to analyze the genome, transcriptome, epigenome, and proteome of individual cells. This review summarizes the various techniques used in single-cell sequencing and provides examples of recent high-impact findings. It also discusses the translational relevance of these technologies and their potential use in clinical trials.

CANCERS (2022)

Article Oncology

Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma

Jason Roszik, Lisa Maria Mustachio, John A. Livingston, Roman Groisberg, Roberto Carmagnani Pestana, Vivek Subbiah, Anthony P. Conley

Summary: Soft tissue sarcomas, rare diseases of mesenchymal origin, display heterogeneity and varying clinical behaviors, making standardized therapy difficult. Studies show high potential of immunotherapy for sarcoma treatment, especially in subtypes with specific genomic alterations and immune cell markers. Sarcomas with high mutational load may be more sensitive to immunotherapy, with potential for developing optimal treatments based on immune composition.

CANCERS (2021)

Article Oncology

Malic Enzyme 1 Absence in Synovial Sarcoma Shifts Antioxidant System Dependence and Increases Sensitivity to Ferroptosis Induction with ACXT-3102

Caitlyn B. Brashears, Bethany C. Prudner, Richa Rathore, Katharine E. Caldwell, Carina A. Dehner, Jane L. Buchanan, Sara E. S. Lange, Neal Poulin, Jennifer K. Sehn, Jason Roszik, Dirk Spitzer, Kevin B. Jones, Regis O'Keefe, Torsten O. Nielsen, Eric B. Taylor, Jason M. Held, William Hawkins, Brian A. Van Tine

Summary: The study investigates the metabolism of synovial sarcoma (SS) and highlights the impact of malic enzyme 1 absence on SS redox homeostasis. The findings suggest that targeting redox homeostasis in ME1-null cancers could be a potential therapeutic approach, with increased susceptibility to ferroptosis induction. These results provide a preclinical rationale for conducting a phase I trial of ACXT-3102 in SS patients.

CLINICAL CANCER RESEARCH (2022)

Review Oncology

Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors

Jacob J. Adashek, Arjun K. Menta, Neha K. Reddy, Aakash P. Desai, Jason Roszik, Vivek Subbiah

Summary: BRAF V600 mutations are prevalent in various nonmelanoma malignancies and can be clinically targeted with BRAF inhibitor therapy, suggesting their potential application in the treatment of nonmelanoma rare malignancies in both adults and children.

MOLECULAR CANCER THERAPEUTICS (2022)

Article Oncology

Cytospin-A Regulates Colorectal Cancer Cell Division and Migration by Modulating Stability of Microtubules and Actin Filaments

Fan Fan, Jason Roszik, Ling Xia, Susmita Ghosh, Rui Wang, Xiangcang Ye, David Hawke, Lee M. Ellis, Rajat Bhattacharya

Summary: This study demonstrates the effects of depleting CYTSA protein on the proliferation and migration of colorectal cancer cells, suggesting that targeting CYTSA may be a novel therapeutic strategy for CRC.

CANCERS (2022)

Article Oncology

EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer

Mihaly Cserepes, Gyorgyi A. Nelhubel, Monika Meilinger-Dobra, Adrienn Herczeg, Dora Turk, Zita Hegedus, Laura Svajda, Erzsebet Raso, Andrea Ladanyi, Kristof Gyorgy Csiko, Istvan Kenessey, Arpad Szoor, Gyorgy Vereb, Eva Remenar, Jozsef Tovari

Summary: In this study, the effects of EGFRvIII and EGFR R521K variants on cetuximab efficacy were investigated. The results showed that the frequency of the EGFRvIII allele in head and neck squamous cell carcinoma patients is less than 1%, indicating that it does not lead to common resistance. EGFR R521K, present in 42% of the patients, was found to reduce cell sensitivity in vitro and in vivo experiments, but this preclinical difference did not correlate with patients' progression-free or overall survival.

CANCERS (2022)

Article Biochemical Research Methods

Taking molecular pathology to the next level: Whole slide multicolor confocal imaging with the Pannoramic Confocal digital pathology scanner

Istvan Rebenku, Ferenc A. Bartha, Tamas Katona, Barbara Zsebik, Geza Antalffy, Lili Takacs, Bela Molnar, Gyorgy Vereb

Summary: The emergence and fast advance of digital pathology allows the acquisition, digital storage, interactive recall and analysis of tissue-level morphology. The rise of fluorescence pathology scanners expands the detection of molecules based on multiplex labeling. The Pannoramic Confocal provides sensitive, quantitative widefield and confocal detection of multiplexed fluorescence signals, with optical sectioning and 3D reconstruction.

CYTOMETRY PART A (2023)

Article Oncology

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Justin T. Moyers, Roberto Carmagnani Pestana, Jason Roszik, David S. Hong, Aung Naing, Siqing Fu, Sarina Piha-Paul, Timothy A. Yap, Daniel Karp, Jordi Rodon, Andy Livingston, Maria Alejandra Zarzour, Vinod Ravi, Shreyaskumar Patel, Robert S. Benjamin, Joseph Ludwig, Cynthia Herzog, Ravin Ratan, Neeta Somaiah, Anthony Conley, Richard Gorlick, Funda Meric-Bernstam, Vivek Subbiah

Summary: In this study, the outcomes of patients with ultrarare sarcomas in Phase 1 trials were assessed. The results showed that the median overall survival of ultrarare sarcomas was similar to common sarcomas, but the objective response rate to treatment was higher. Genomic selection played a significant role in identifying molecular subsets likely to benefit from targeted therapy in Phase 1 trials.

CLINICAL CANCER RESEARCH (2023)

Article Oncology

Novel murine glioblastoma models that reflect the immunotherapy resistance profile of a human disease

Chao-Hsien Chen, Renee L. Chin, Genevieve P. Hartley, Spencer T. Lea, Brian J. Engel, Cheng-En Hsieh, Rishika Prasad, Jason Roszik, Takashi Shingu, Gregory A. Lizee, Amy B. Heimberger, Steven W. Millward, Jian Hu, David S. Hong, Michael A. Curran

Summary: This study developed murine glioblastoma stem cell lines with clinically relevant genetic mutations and evaluated their immune sensitivities in immunocompetent hosts. The results showed that different cell lines have varying sensitivities to T cell immune checkpoint blockade, and there are differences between the brain and flank. Immunological analysis revealed that upregulation of PD-L1 on myeloid stroma establishes immune privilege in the brain. However, QPP7 cell line showed response to immunotherapy even in the brain due to its elevated neoantigen burden. These mouse models can be used for mechanistic discovery and evaluation of immune therapies.

NEURO-ONCOLOGY (2023)

Article Oncology

Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth

Chandrani Chattopadhyay, Rajat Bhattacharya, Jason Roszik, Fatima S. Khan, Gabrielle A. Wells, Hugo Villanueva, Yong Qin, Rishav Bhattacharya, Sapna P. Patel, Elizabeth A. Grimm

Summary: Researchers found that inhibiting the IGF-1 signaling pathway can reduce cell survival and migration, while promoting apoptosis in UM. In vivo models also showed a decrease in tumor growth with this treatment.

CANCERS (2022)

Article Oncology

Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer

Susmita Ghosh, Fan Fan, Reid T. Powell, Jason Roszik, Yong Sung Park, Clifford Stephan, Manu Sebastian, Lin Tan, Alexey Sorokin, Philip L. Lorenzi, Scott Kopetz, Lee M. Ellis, Rajat Bhattacharya

Summary: Mutations in KRAS are common in metastatic colorectal cancer (mCRC) and direct targeting of these mutations is difficult. In this study, we found that the combination of trametinib and vincristine showed significant efficacy in inhibiting tumor growth and inducing apoptosis in KRAS-mutant colorectal cancer. The combination also inhibited the RAS-RAF-MEK and PI3K-AKT-mTOR survival pathways.

MOLECULAR CANCER THERAPEUTICS (2023)

Article Oncology

Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion

Yasunari Fukuda, Sun-Hee Kim, Matias A. Bustos, Sung-Nam Cho, Jason Roszik, Jared K. Burks, Hong Kim, Dave S. B. Hoon, Elizabeth A. Grimm, Suhendan Ekmekcioglu

Summary: The arachidonic acid pathway, specifically microsomal prostaglandin E2 synthase 1 (mPGES-1), plays important roles in regulating tumor immunity in melanoma. The study suggests that inhibiting mPGES-1 can reduce collagen deposition and T-cell exhaustion, thereby reinforcing immunotherapy in melanoma.

CANCER RESEARCH COMMUNICATIONS (2023)

Article Oncology

Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer

Kyaw Z. Thein, Amadeo B. Biter, Kimberly C. Banks, Andrew W. Duda, Jennifer Saam, Jason Roszik, Filip Janku, Ferdinandos Skoulidis, John V. Heymach, Scott Kopetz, Funda Meric-Bernstam, David S. Hong

Summary: This study conducted a comprehensive analysis of KRAS(G12C) mutations in different types of cancer through liquid biopsy. The results showed that KRAS(G12C) mutations were detected in various cancers, with the highest detection rate in lung cancer.

JCO PRECISION ONCOLOGY (2022)

Article Oncology

Real-world Studies Link NSAID Use to Improved Overall Lung Cancer Survival

Jason Roszik, J. Jack Lee, Yi-Hung Wu, Xi Liu, Masanori Kawakami, Jonathan M. Kurie, Anas Belouali, Simina M. Boca, Samir Gupta, Robert A. Beckman, Subha Madhavan, Ethan Dmitrovsky

Summary: This study investigates whether NSAIDs improve overall survival in non-small cell lung cancer (NSCLC) through real-world studies and natural language processing (NLP). The results show a statistically significant association between NSAID use and increased NSCLC survival across different stages, histopathology, gender, smoking history, and demographic groups. These findings provide a rationale for future randomized trials of NSAIDs in NSCLC.

CANCER RESEARCH COMMUNICATIONS (2022)

暂无数据